S Korean firm specialising in life science technology to set ground in Qatar

A South Korean company specialising in genome editing has announced plans to initiate the development of treatments for genetic diseases in Qatar with local collaboration.

“Qatar stands out in the Gulf region as a centre for medical excellence, having global educational institutions providing research and development (R&D), training, and education for the future pioneers in the field of medicine and science.
“We at G+FLAS have recognised this and have initiated our goal of establishing a centre in Doha to share our R&D experience in genome editing, CRISPR PLUS technology,” the company said in a statement.
G+FLAS, which is based in South Korea, was founded in 2014 by its CEO, Dr Sunghwa Choe, and specialises in CRISPR-Cas genome editing technology and applicational technology development; product development and production of biomedicine, and anti-cancer drugs, among others; plant-derived pharmaceuticals; genetic disease treatment; precision targeted therapy; CRISPR Cancerase; non-GMO; novel seed for arid lands;

Read More
Read More